Search research articles
Contact Us
Filters
Showing results (381-390 of 941) with videos related to
Page
of 95
Sort By:
Oncotarget
|
February 13, 2025
Correction: Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass
Chih-Cheng Yang, Ladan Fazli, Salvatore Loguercio, et al.
Pharmaceutical Research
|
January 23, 2020
Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release
Veronika Schmitt, Claudia Kesch, John K Jackson, et al.
The Prostate
|
August 30, 2018
SRRM4 gene expression correlates with neuroendocrine prostate cancer
Yinan Li, Qingfu Zhang, Jessica Lovnicki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 6, 2025
Comparative analysis of apixaban vs. enoxaparin for thromboprophylaxis after radical cystectomy A single-center, observational, before-after study
Cory S Macklin, Gabrielle Reznik, Martin E Gleave, et al.
Experimental Cell Research
|
February 26, 2022
The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation
Xiaodong Weng, Jing Li, Qiunong Guan, et al.
Immunology and Cell Biology
|
September 16, 2020
Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys
Xiaodong Weng, Haimei Zhao, Qiunong Guan, et al.
Reviews in Urology
|
September 21, 2006
Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy
M I Resnick, E D Crawford, M E Gleave, et al.
Cancer Chemotherapy and Pharmacology
|
May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Clinical and Experimental Pharmacology & Physiology
|
July 28, 2001
General practitioner participation in the second Australian National Blood Pressure Study (ANBP2)
C M Reid, P Ryan, M Nelson, et al.
Cancer Research
|
July 9, 2011
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
Francois Lamoureux, Christian Thomas, Min-Jean Yin, et al.
Page
of 95
Search research articles
Search
Showing results (381-390 of 941) with videos related to
Sort By:
Page
of 95
Oncotarget
|
February 13, 2025
Correction: Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass
Chih-Cheng Yang, Ladan Fazli, Salvatore Loguercio, et al.
Pharmaceutical Research
|
January 23, 2020
Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release
Veronika Schmitt, Claudia Kesch, John K Jackson, et al.
The Prostate
|
August 30, 2018
SRRM4 gene expression correlates with neuroendocrine prostate cancer
Yinan Li, Qingfu Zhang, Jessica Lovnicki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 6, 2025
Comparative analysis of apixaban vs. enoxaparin for thromboprophylaxis after radical cystectomy A single-center, observational, before-after study
Cory S Macklin, Gabrielle Reznik, Martin E Gleave, et al.
Experimental Cell Research
|
February 26, 2022
The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation
Xiaodong Weng, Jing Li, Qiunong Guan, et al.
Immunology and Cell Biology
|
September 16, 2020
Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys
Xiaodong Weng, Haimei Zhao, Qiunong Guan, et al.
Reviews in Urology
|
September 21, 2006
Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy
M I Resnick, E D Crawford, M E Gleave, et al.
Cancer Chemotherapy and Pharmacology
|
May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumors
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Clinical and Experimental Pharmacology & Physiology
|
July 28, 2001
General practitioner participation in the second Australian National Blood Pressure Study (ANBP2)
C M Reid, P Ryan, M Nelson, et al.
Cancer Research
|
July 9, 2011
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
Francois Lamoureux, Christian Thomas, Min-Jean Yin, et al.
Page
of 95